Children and Teenagers Under-Represented in Multidrug-Resistant Tuberculosis Treatment: Key Study Findings
New Delhi: Recent research has highlighted the underrepresentation of children and teenagers in treatment statistics for multidrug-resistant tuberculosis (MDR-TB). Experts are calling for increased efforts to identify and treat this often-overlooked demographic.
Understanding Multidrug-Resistant Tuberculosis
Multidrug-resistant tuberculosis occurs when the bacteria causing the infection develop resistance to at least two first-line drugs. Among these, rifampicin is crucial as a first-line treatment recommended by the World Health Organization (WHO).
Study Reveals Key Trends
Researchers from various institutions reviewed multiple studies to understand the trends in MDR-TB treatment among children and teenagers aged 18 or below. One comprehensive review, involving 42 studies and over 23,369 participants mostly from India and South Africa, published in The Lancet Child and Adolescent Health, found that nearly three-quarters of these patients were successfully treated with an average treatment duration of 16 months.
Focus Needed on Specific Age Groups
The report emphasized that younger children and those with clinically diagnosed MDR-TB are disproportionately under-represented in treatment data. Researchers noted that children under five, a critical age group where most TB-related deaths occur globally, are even less likely to be identified and treated. Conversely, older teens (15-19 years) accounted for nearly 70% of participants, reflecting their similarity in disease patterns to adults, making diagnosis more straightforward through laboratory tests.
Addressing Extensively Drug-Resistant TB
Another review, conducted by researchers from the University of Toronto and including studies from India, examined extensively drug-resistant TB (XDR-TB), where bacteria are resistant to nearly all available treatments. This study, published in PLoS Global Public Health, found high success rates in treating children with XDR-TB (around 90%) but noted a significant underreporting of cases.
Challenges in Identifying and Treating Pediatrics Cases
Shorter treatment durations (ranging from 6 to 27 months) were reported for XDR-TB cases in children, indicating some efficacy. However, the underrepresentation of pediatric patients in global statistics poses challenges in addressing this critical public health issue.
Call for Targeted Efforts
Experts stress the need for targeted interventions aimed at identifying and treating MDR-TB and XDR-TB in children and adolescents. Incorporating these younger age groups into case-finding efforts could significantly improve treatment outcomes and reduce the spread of these drug-resistant strains.
Significance of the Findings
The findings underscore the importance of addressing the unique challenges faced by children and teenagers in MDR-TB treatment. By prioritizing these groups, public health initiatives can more effectively combat the global burden of tuberculosis.
Do you have any insights or experiences to share regarding TB treatment in children and teenagers? Join the conversation by leaving a comment below or subscribe to our newsletter for more updates.
